The U.S. government agreed to pay Pfizer Inc nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral treatment Paxlovid, the company said on Tuesday. The new purchase supplements the 20 million courses previously bought by the United States and delivery is planned by early 2023, Pfizer said in a statement.
U.S. to pay Pfizer nearly $2 bln for more Paxlovid courses in 2023
Date: